Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2019 February;63(1) > Journal of Neurosurgical Sciences 2019 February;63(1):42-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   

Journal of Neurosurgical Sciences 2019 February;63(1):42-9

DOI: 10.23736/S0390-5616.17.03989-3

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

Elevated brain derived neurotrophic factor levels in plasma reflect in vivo functional viability of infused mesenchymal stem cells for stroke in rats

Hideyuki NAKAMURA 1, Yuichi SASAKI 1, Masanori SASAKI 1, 2, 3 , Yuko KATAOKA-SASAKI 1, Shinichi OKA 1, Masahito NAKAZAKI 1, Takahiro Namioka 1, Ai NAMIOKA 1, Rie ONODERA 1, Junpei SUZUKI 1, Hiroshi NAGAHAMA 1, Takeshi MIKAMI 4, Masahiko WANIBUCHI 4, Jeffery D. KOCSIS 2, 3, Osamu HONMOU 1, 2, 3

1 Department of Neural Regenerative Medicine, Research Institute for Frontier Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan; 2 Department of Neurology, Yale University School of Medicine, New Haven, CT, USA; 3 Center for Neuroscience and Regeneration Research, VA Connecticut Healthcare System, West Haven, CT, USA; 4 Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Japan


PDF


BACKGROUND: Intravenous infusion of mesenchymal stem cells (MSCs) derived from adult bone marrow elicits functional recovery in rat stroke models and clinical studies in patients are ongoing. Brain derived neurotrophic factor (BDNF) is a neurotrophic factor produced by MSCs and may contribute to their therapeutic efficacy. The purpose of the current study was to determine if BDNF is elevated in infarcted brain and in which compartment of blood (plasma or serum) after intravenous MSC infusion in a middle cerebral artery occlusion (MCAO) model in the rat.
METHODS: In rats, a permanent middle cerebral artery occlusion (MCAO) was induced by intraluminal vascular occlusion with a microfilament and MSCs were intravenously administered 6 h after right MCAO induction. Enzyme-linked immunosorbent assay (ELISA) analysis of brain, serum and plasma BDNF were performed after the MSC infusion following the MCAO induction. Lesion volume was assessed using magnetic resonance imaging. Functional outcome was assessed using the Limb Placement Test.
RESULTS: Infused MSCs reduced lesion volume and elicited functional improvement compared to the vehicle infused group. ELISA analysis of the MSC treated group revealed an increase BDNF levels in the infarcted hemisphere of the brain and plasma, but not in serum. The MSC group showed a greater increase in BDNF levels than sham control. In the MSC group, the expression of increased plasma BDNF levels correlated with increased brain BDNF levels.
CONCLUSIONS: These results support the hypothesis that BDNF levels in plasma, but not serum, may be more appropriate to detect circulating BDNF in vivo following MSC infusion in a cerebral infarction rat model of ischemic stroke. Further, plasma BDNF might reflect in vivo functional viability of infused MSCs after stroke.


KEY WORDS: Mesenchymal stem cell - Stroke - Cell- and tissue-based therapy

top of page